|| Checking for direct PDF access through Ovid
The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1–3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients.We analyzed, retrospectively, 457 patients randomized in FASG 02 and 07 trials who received: tamoxifen alone (30 mg/day, 3 years); or FEC50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2, six cycles every 21 days) plus tamoxifen started concurrently. Radiotherapy was delivered after the third cycle in FASG 02 trial, and after the sixth in FASG 07 trial.The 9-year DFS rates were 72% with tamoxifen and 84% with FEC50-tamoxifen (P=0.008). The multivariate analysis showed that pathological tumor size >2 cm was an independent prognostic factor (P=0.002), and treatment effects remained significantly in favor of chemoendocrine therapy (P=0.0008). The 9-year overall survival rates were 78% and 86%, respectively (P=0.11). In the multivariate model, there was a trend in favor of chemoendocrine therapy (P=0.07).The addition of FEC50 adjuvant chemotherapy to tamoxifen significantly improves long-term DFS in N1–3, ER+ and postmenopausal women. Chemoendocrine therapy seems to be more effective than tamoxifen in terms of long-term survival.